The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / High Cost of Specialty Drugs Demands Action

High Cost of Specialty Drugs Demands Action

July 6, 2021 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Another concern is switching patients who have achieved disease stability on their current biologic therapy. “We need more pharmacovigilance and real-world data so we can see switching patterns, as well as why people switch to a biosimilar from a biologic or other biosimilar, and what happens as a result of these switches,” says Dr. Gewanter.

You Might Also Like
  • High Cost of DMARDs Could Limit Medicare Patients’ Treatment Adherence
  • ACR/ARHP Annual Meeting 2012: Federal Act Aims to Make New Biologic Drugs Available to Rheumatology Patients at a Lower Cost
  • Alliance Working to Rein in Power of PBMs
Explore This Issue
August 2021
Also By This Author
  • Studies Highlight Risk of Damage from Lupus Treatments

Such data will have clinical relevance only if the drugs are placed on formulary. For now, PBMs appear to hold the stronger hand over providers. “Changing PBM practice could be a game-changer in the way that drug prices in the U.S. are set, especially for people taking specialty drugs for conditions like chronic autoimmune disease or cancer, and can change the outlook for cost and access to medications,” says Dr. Worthing.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Until and if such changes take place, Dr. Worthing says providers can continue to advocate for their patients by appealing denials of drug preauthorizations, alerting state insurance commissioners of PBM practices that are adversely affecting health decisions between provider and patient, and encouraging patients to advocate for themselves.

For more information on how PBMs work and advocacy efforts to change their practices, see https://atapadvocates.com/the-pbm-problem.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Mary Beth Nierengarten is a freelance medical journalist based in Minneapolis.

 

Table 1: Practices by Pharmacy Benefit Managers (PBMs)
Formulary Construction PBMs basically enter into auction-style bidding with drug manufacturers and are incentivized to choose drugs with the highest rebates (or total price concessions) for favorable placement on formulary tiers.* The PBM pockets a portion of the rebate as profits, so higher rebates yield more profit. To remain competitive and offset the cost of the rebates, drug companies typically increase the list price of the drug. That increased price is passed on to the patient.

Drugs with a higher list price can push other drugs off a formulary or to a higher tier, resulting in patients being forced to switch therapies, adhere to step therapy protocols or make other changes. Frequent formulary changes make continuity of care challenging.

Nonmedical Switching This occurs when a patient is switched from one medication to another for reasons other than efficacy, health or safety.
Copay Accumulator Programs These programs limit drug manufacturer contributions to patients’ copays and out-of-pocket deductible expenses by disallowing the use of money from copay assistance programs toward these expenses.
White Bagging Arrangements between a payer and selected pharmacies to have patients’ medications sent directly to the site of care. This practice can compromise patient safety and create clinical challenges when unpredictable changes occur, such as the need to adjust dosing, a medication not delivered in time for a patient’s appointment or a patient who can’t make it to an appointment.

*Although “rebate” is commonly used to denote the price concessions that PBMs negotiate with drug manufacturers, it is just one component of the net price, which also includes other discount fees and defined terms. A more accurate term preferred by some is “total price concessions.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Legislation & Advocacy, Practice Management Tagged With: drug pricing, pharmacy benefit managers (PBMs)Issue: August 2021

You Might Also Like:
  • High Cost of DMARDs Could Limit Medicare Patients’ Treatment Adherence
  • ACR/ARHP Annual Meeting 2012: Federal Act Aims to Make New Biologic Drugs Available to Rheumatology Patients at a Lower Cost
  • Alliance Working to Rein in Power of PBMs
  • Rheumatologists Air Frustrations with Pharmacy Benefit Managers at Annual Meeting

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)